Sarepta Therapeutics Inc - Asset Resilience Ratio
Sarepta Therapeutics Inc (SRPT) has an Asset Resilience Ratio of 6.81% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SRPT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1995–2024)
This chart shows how Sarepta Therapeutics Inc's Asset Resilience Ratio has changed over time. See Sarepta Therapeutics Inc (SRPT) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sarepta Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SRPT market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $237.92 Million | 6.81% |
| Total Liquid Assets | $237.92 Million | 6.81% |
Asset Resilience Insights
- Limited Liquidity: Sarepta Therapeutics Inc maintains only 6.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sarepta Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Sarepta Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Sarepta Therapeutics Inc (1995–2024)
The table below shows the annual Asset Resilience Ratio data for Sarepta Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.35% | $251.78 Million | $3.96 Billion | -31.87pp |
| 2023-12-31 | 38.22% | $1.25 Billion | $3.26 Billion | +5.54pp |
| 2022-12-31 | 32.69% | $1.02 Billion | $3.13 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $3.15 Billion | -- |
| 2020-12-31 | 14.61% | $435.92 Million | $2.98 Billion | -1.29pp |
| 2019-12-31 | 15.89% | $289.67 Million | $1.82 Billion | -33.02pp |
| 2018-12-31 | 48.91% | $803.08 Million | $1.64 Billion | +12.26pp |
| 2017-12-31 | 36.65% | $479.37 Million | $1.31 Billion | -9.43pp |
| 2016-12-31 | 46.08% | $195.43 Million | $424.10 Million | +5.10pp |
| 2015-12-31 | 40.98% | $112.19 Million | $273.78 Million | -5.39pp |
| 2014-12-31 | 46.37% | $136.79 Million | $295.03 Million | +43.88pp |
| 2013-12-31 | 2.49% | $7.25 Million | $291.57 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $204.99 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $54.37 Million | -- |
| 2009-12-31 | 0.28% | $171.00K | $60.03 Million | -0.82pp |
| 2008-12-31 | 1.10% | $282.06K | $25.54 Million | +0.40pp |
| 2007-12-31 | 0.70% | $271.85K | $38.64 Million | -31.09pp |
| 2006-12-31 | 31.80% | $12.99 Million | $40.86 Million | +9.72pp |
| 2005-12-31 | 22.08% | $12.45 Million | $56.41 Million | +12.05pp |
| 2004-12-31 | 10.03% | $2.86 Million | $28.52 Million | -43.16pp |
| 2003-12-31 | 53.19% | $25.07 Million | $47.15 Million | +22.04pp |
| 2002-12-31 | 31.15% | $8.91 Million | $28.60 Million | -11.82pp |
| 2001-12-31 | 42.96% | $14.53 Million | $33.82 Million | +25.25pp |
| 2000-12-31 | 17.71% | $6.21 Million | $35.09 Million | -4.77pp |
| 1999-12-31 | 22.48% | $2.90 Million | $12.90 Million | +13.78pp |
| 1995-12-31 | 8.70% | $200.00K | $2.30 Million | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exo… Read more